Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 5/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | KLK7 | P49862 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | PRCP | P42785 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6201175 | 1.00 | PREP (0.58) | PREPHSD17B10KLK7NPSR1TSHR | |
| SCHEMBL2960273 | 0.95 | PREP (0.57) | PREPHSD17B10KLK7NPSR1 | |
| SCHEMBL13780263 | 0.94 | HSD17B10 (0.58) | PREPHSD17B10KLK7NPSR1UCHL1 | |
| SCHEMBL4974458 | 0.91 | HSD17B10 (0.55) | PREPHSD17B10KLK7UCHL1 | |
| SCHEMBL8750859 | 0.89 | PREP (0.68) | PREPHSD17B10KLK7NPSR1TSHR | |
| SCHEMBL8750947 | 0.89 | PREP (0.68) | PREPHSD17B10KLK7NPSR1TSHR | |
| SCHEMBL8750854 | 0.89 | PREP (0.68) | PREPHSD17B10KLK7NPSR1TSHR | |
| SCHEMBL11262912 | 0.88 | PREP (0.69) | PREPHSD17B10KLK7NPSR1TSHR | |
| SCHEMBL11262909 | 0.88 | PREP (0.69) | PREPHSD17B10KLK7NPSR1TSHR | |
| SCHEMBL488744 | 0.87 | PREP (0.68) | PREPKLK7NPSR1TSHRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1399436-B1 | OXYTOCIN AGONISTS | FERRING BV (NL) | 2005-03-16 | — | — | EP | disclosed |
| US-20040235753-A1 | Oxytocin agonists | PITT GRAY ROBERT WILLIAM (GB) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235753-A1 | Oxytocin agonists | OXTR, GNRHR, PRLHR | PREP 2725/4885HSD17B10 1180/4885KLK7 892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.